Mereo BioPharma (MREO) Net Income (2023 - 2026)

Mereo BioPharma (MREO) has reported Net Income for 4 consecutive years, with -$6.7 million the latest figure, recorded in Q1 2026.

• Quarterly Net Income rose 47.86% year-over-year to -$6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46.1 million (up 20.55% YoY) and the FY2025 annual result came in at -$52.3 million, up 3.37% from the prior year.
• Net Income grew to -$6.7 million in Q1 2026 per MREO's latest filing, from -$17.8 million in the prior quarter.
• Over the last five years, Net Income for MREO reached as high as -$6.5 million in Q3 2023 and fell as low as -$17.9 million in Q4 2024.
• A 4-year average of -$11.7 million and a median of -$12.2 million in 2023 frame the typical range for Net Income.
• Annual changes were most pronounced in 2024 — Net Income slumped 129.69% — and 2025, when it surged 53.18%.
• Year by year, Net Income stood at -$9.1 million in 2023, then slumped by 96.61% to -$17.9 million in 2024, then gained by 0.8% to -$17.8 million in 2025, then jumped by 62.18% to -$6.7 million in 2026.
• According to Business Quant data, Net Income over the past three periods registered -$6.7 million, -$17.8 million, and -$7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.